Mayo Clinic Talks

 
 
  • Autoimmune disorders: An emerging risk factor for CV disease   For several decades, rheumatologists have documented the elevated risk for cardiovascular disease of patients with autoimmune disorders such as rheumatoid arthritis and lupus, but it has only relatively recently entered the cardiovascular literature.
  • Heart transplantation: Peri- and postoperative management   In a rapidly changing field, they share their expertise with the latest options in immunosuppressive strategy and thoughts on the long-term management of those who have had a transplant.
  • Robotic mitral-valve repair   Dr Rakesh Suri joins Dr Hector Michelena to discuss the genesis of the minimally invasive robotic approach to mitral-valve repair with tips on timing, safety, and a review of the relative advantages of the newer approach.
  • Tips for new TAVR centers   What's the pulse of cardiology today? American College of Cardiology president Dr David Holmes talks to Dr Bernard Gersh about the past year in cardiology—addressing the challenges of practice, education and learning, reimbursement, and appropriateness cr
  • Minimally invasive approaches to congenital heart defects   What's the pulse of cardiology today? American College of Cardiology president Dr David Holmes talks to Dr Bernard Gersh about the past year in cardiology—addressing the challenges of practice, education and learning, reimbursement, and appropriateness cr
  • Stem-cell therapy for hypoplastic left heart syndrome   After showing promising results in early-phase trials for ischemic heart disease, stem-cell therapy is now being examined as a possible mechanism to treat congenital diseases such as hyperplastic left heart syndrome.
  • #29: What's different about heart disease in women?   After years of being omitted from clinical trials, research is finally taking strides to recognize the specificity of heart disease in women. Dr Sharon Mulvagh joins Dr Bernard Gersh to ask why wouldn't there be differences in heart disease between women
  • #28: Cardiac device infections: From A to Z   Despite the ever shrinking size of devices and our greater technical expertise, there has been a disproportionate rise in the rate infections associated with cardiac devices. Drs Raul Espinosa and M Rizwan Sohail join Dr Charanjit (Chet) Rihal to discuss
  • #27: Heart transplantation: Selecting the ideal candidate   Which patients are the best candidates for heart transplantation? Drs Sudhir Kushwaha and Rocky Daly-respectively the medical and surgical directors of the Heart Transplantation and VAD therapy program at Mayo Clinic-review the steps to selecting patient
  • #26: A sign of the times: Social media's impact on SCAD research   Research on spontaneous coronary artery dissection (SCAD) at the Mayo Clinic is a telling example of "patient-initiated" research made possible by social media. Dr Sharonne Hayes discusses with Dr Sharon Mulvagh the genesis of the SCAD project and the...
  • #25: Preventing AF: The role of ACE inhibitors and ARBs   Popular treatment options fail to recognize AF as a consequence of other problems and instead attempt to treat atrial fibrillation as if it were the problem itself.
  • #24: The epidemiology of heart failure   Dr Veronique Roger joins Dr Bernard Gersh to review the latest data and share insight into what is now termed an epidemic.
  • #23: Valve repair: Who, where, why   Dr Vuyisile Nkomo is joined by Dr Joseph Dearani for an update on the latest information pertaining to surgical valve repair.
  • #22: Getting to the root of the problem: Thoracic and endovascular surgery   What's the latest on the surgical treatment of thoracic aortic disease? Dr Juan Bowen catches up with Dr Alberto Pochettino on issues such as safety of surgical procedures and when to refer a patient for surgery...
  • #19: The hormonal dilemma: Unraveling an "acute confusional state"   Where do things stand with hormone-replacement therapy? Dr Sharon Mulvagh joins Dr Bernard Gersh to shine light on the notoriously complicated data—including the HERS, WHI, KEEPS, and DOPS trials—and show why the trial results are not as contradictory as
  • #18: Radiofrequency ablation in AF   Despite years of research, our understanding of this field remains limited. Dr Douglas Packer joins the show to discuss the pathophysiology of atrial fibrillation in regard to the targets for radiofrequency ablation, how the procedure has changed in the p
  • #17: Treating ventricular tachycardia in patients without structural heart disease   Dr Bernard Gersh asks Dr Samuel Asirvatham about the syndromes that categorize patients who have ventricular tachycardia in the absence of structural heart disease and what the treatment options—including ablation—are for these patients.
  • #16: LVAD therapy for patients with congestive heart failure   Guest host Dr Margaret Redfield discusses the basics of left ventricular assist devices (LVADs)—as bridge to transplant, destination therapy, and bridge to recovery—with leading heart-failure surgeon Dr Soon Park. What role are LVADs playing in HF?
  • #15: Healthcare reform--All doom and gloom?   In the context of shrinking funds and an aging population (10 000 people turn 65 each day), what is the status of healthcare reform in the US? Guest host Dr Chet Rihal catches up with Dr Ray Gibbons for a frank discussion on where things stand, what ...
  • #14: Sudden cardiac death in the young: The role of arrhythmogenic right ventricular dysplasia   Sudden cardiac death in the young: The role of arrhythmogenic right ventricular dysplasia